Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 2018

View Archived Issues

Ultra-deep sequencing brings new cancer gene insights, and questions

Turn Therapeutics reports in vivo data for OV-02 for shingles of the eye

Whole-exome sequencing expands the known causative genes of hereditary distal renal tubular acidosis

Pivotal phase III KEYNOTE-426 study meets both primary endpoints

First-in-human study of [11C]JNJ-54173717, a PET tracer for assessing neuroinflammation

DS Biopharma presents positive results from Advance phase IIb study of oral DS-107

Jiangsu HengRui studies SHR-1209 in phase I in China

Midkine as a potential new biomarker of ovarian reserve in PCOS

Homology Medicines' gene therapy for PKU shows promising preclinical results

First phase III results from the SAkuraSky study of satralizumab in NMOSD patients

IPR-166 enhances cognitive performance in a schizophrenia-like mouse model

NeuroVive drug candidate shows efficacy in model for mitochondrial disease

Dupilumab results in highly significant improvements in lung function in adolescents with asthma

Encouraging phase I results for camrelizumab in nasopharyngeal carcinoma

Efficacy and safety of lurbinectedin in BRCA1/2 mutated or unselected metastatic breast cancer

PIKfyve inhibitors identified at Nanosyn

ST Pharm discovers new HIV integrase inhibitors

Results of phase I trial of epacadostat plus pembrolizumab in advanced solid tumors

Amgen presents new Mcl-1 inhibitors

Aelix and Gilead collaborate to study HTI T-cell vaccine with vesatolimod in HIV

AbbVie and Morphic Therapeutic to develop oral integrin therapeutics for fibrotic diseases

HERA-CD40L, a hexavalent CD40 agonist, induces antitumor immune responses both in vitro and in vivo

Increased pyruvate dehydrogenase kinase has key role in pathogenesis of nonalcoholic liver disease

Nrf2 pathway, novel therapeutic target for the treatment of cognitive impairment in type 1 diabetes

Novel CNDP1 transgenic mice show protective role of renal carnosine against diabetic nephropathy

Merrimack terminates SHERLOC study of MM-121 in NSCLC for futility

Menarini initiates phase Ib study of MEN-1611 for HER2-positive breast cancer